Application of Robot-assisted Pancreaticobiliary Junction Resection in Benign Duodenal Tumors
December 20th, 2024
The current protocol delineates the use of robot-assisted pancreaticobiliary junction resection for the surgical management of benign duodenal tumors. This approach provides an effective solution for treating these tumors while minimizing duodenal loss and reducing associated complications.
To begin, insert a 10-millimeter trocar into the created pneumoperitoneum and introduce the laparoscope through the third arm of the robot. Explore the intraperitoneal organs using the laparoscope to confirm the absence of ascites and ensure there are no signs of tumor implantation or metastasis. After inserting the three 10-millimeter trocars, prepare two 12-millimeter auxiliary ports, one at the midpoint between trocars 2 and 3 on a vertical line, and the other medial to the left midclavicular line.
Connect the robotic operating lever and begin the laparoscopic operation with robotic assistance. Using a kocher incision, mobilize the descending and horizontal parts of the duodenum. Using an ultrasonic knife, dissect approximately eight centimeters of the descending part of the duodenum and identify the duodenal papillary mass.
Then, with the ultrasonic knife, incise the duodenal fold and muscle layer to a depth of 3 to 5 millimeters around the tumor. Fully excise the tumor and freeze the specimens immediately for examination. Using a 4.0 absorbable suture, discontinuously anastomose the incised duodenal fold, muscle layer, and the stump of the confluent part of the biliary pancreatic duct.
Place a stent tube to support the anastomosis and secure the stent into the distal part of the duodenum with a 4.0 prolene suture. Using a 3.0 putus suture, intermittently suture the mucosal layer and plasma muscle layer of the duodenal incision to bury the wound. Finally, rinse the abdominal cavity with saline to check for bleeding points and place a drain at Winslow foramena and the paraduodenum.
Close the incision with a 4.0 silk suture to conclude the operation. The robotic assisted pancreatic cobiliary junction resection was completed in 3.5 hours with minimal intraoperative bleeding volume of 30 milliliters, eliminating the need for a blood transfusion. Postoperative drainage amylase levels decreased significantly from 8, 855 units per liter on postoperative Day 2 to 49.96 units per liter on postoperative Day 9, indicating recovery without pancreatic complications.
Drain total bilirubin levels decreased from 27.45 micromoles per liter on postoperative Day 3 to 9.3 micromoles per liter on Day 9, reflecting improved bile duct function and absence of leakage. Pathological findings confirmed the presence of a duodenal papillary villous tubular adenoma consistent with preoperative diagnoses. Postoperative imaging showed complete removal of the duodenal tumor and accurate placement of the biliary stent supporting the efficacy of the surgical technique.
Overview
This protocol describes the robot-assisted pancreaticobiliary junction resection for benign duodenal tumors. The technique aims to minimize duodenal loss and reduce complications.
Key Study Components
Area of Science
- Surgery
- Robotic assistance
- Oncology
Background
- Benign duodenal tumors can pose surgical challenges.
- Traditional methods may lead to significant duodenal loss.
- Robotic techniques offer precision and reduced complications.
- This study explores a novel surgical approach.
Purpose of Study
- To evaluate the effectiveness of robotic assistance in surgery.
- To minimize complications associated with duodenal tumor resection.
- To enhance surgical outcomes for patients with benign tumors.
Methods Used
- Insertion of trocars for laparoscopic access.
- Use of a laparoscope to explore intraperitoneal organs.
- Mobilization of the duodenum using a kocher incision.
- Dissection of the duodenal papillary mass with an ultrasonic knife.
Main Results
- Successful identification and mobilization of the duodenum.
- Effective dissection of the tumor with minimal duodenal loss.
- Reduction in surgical complications compared to traditional methods.
- Enhanced precision in tumor resection using robotic assistance.
Conclusions
- Robot-assisted surgery is a viable option for benign duodenal tumors.
- This approach minimizes complications and preserves duodenal integrity.
- Further studies are needed to validate long-term outcomes.
Frequently Asked Questions
Executive Industry Relevance
Robot-assisted pancreaticobiliary junction resection for benign duodenal tumors exemplifies the integration of advanced surgical technology to enhance procedural precision and minimize tissue trauma. This approach supports improved perioperative outcomes and reduces the risk of postoperative complications, directly impacting surgical innovation pipelines in minimally invasive interventions. The method's reproducibility and quantitative monitoring of recovery markers position it as a valuable asset for translational research and surgical device development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables precise anatomical dissection and real-time assessment of tissue response.
- Facilitates evaluation of surgical device performance in complex anatomical regions.
- Supports functional validation of perioperative monitoring biomarkers.
Screening & Assay Development
- Provides a reproducible surgical workflow for evaluating device-assisted interventions.
- Generates quantitative outputs such as amylase and bilirubin levels for objective assessment.
- Enables standardization of perioperative protocols for downstream comparative studies.
Translational & Preclinical Research
- Aligns with enhanced recovery protocols to inform translational biomarker strategies.
- Supports continuity from surgical innovation to preclinical validation of device safety and efficacy.
- Offers a platform for risk-adjusted evaluation of new surgical technologies.
Pipeline & Workflow Integration
This robotic surgical technique fits within the continuum from device concept validation through preclinical assessment and translational research. Its quantitative monitoring and reproducibility facilitate integration into surgical innovation pipelines.
- Discovery Biology: Supports hypothesis testing for device-tissue interaction and perioperative biomarker response.
- Screening: Enables standardized evaluation of surgical outcomes using objective biochemical markers.
- Analytics: Provides measurable outputs such as drainage amylase and bilirubin for comparative analytics.
- Translational Research: Informs ERAS protocol development and device safety assessment in preclinical models.
- Enterprise Reuse: Establishes a reusable workflow for evaluating robotic surgical interventions across indications.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence in surgical device performance and perioperative biomarker utility.
- Operational Value: Improves standardization, reproducibility, and scalability of complex surgical procedures.
- Strategic Value: Enables data-driven go/no-go decisions for surgical technology advancement.
- Portfolio Impact: Supports risk-adjusted prioritization of device development and translational research investments.
Implementation Considerations
- Requires specialized surgical expertise in robotic systems and perioperative management.
- Demands access to advanced robotic instrumentation and real-time biochemical monitoring infrastructure.
- Necessitates cross-team standardization of perioperative protocols and data collection.
- Adaptation may be needed for different anatomical or disease contexts based on vascular and tissue characteristics.
- Practical limitations include the complexity of the procedure and the need for thorough preoperative evaluation.
